Chimera Translational Research Fraternity Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 09-12-2024
- Paid Up Capital ₹ 1.00 Cr
as on 09-12-2024
- Company Age 6 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -9.06%
(FY 2022)
- Profit 29.61%
(FY 2022)
- Ebitda 35.94%
(FY 2022)
- Net Worth -55.26%
(FY 2022)
- Total Assets -26.02%
(FY 2022)
About Chimera Translational Research Fraternity
The Corporate was formerly known as Vimarsh Bio Innovations India Private Limited. The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Anoushka Raina and Vikash Mishra serve as directors at the Company.
- CIN/LLPIN
U74999DL2018PTC328388
- Company No.
328388
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Jan 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Chimera Translational Research Fraternity?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anoushka Raina  | Director | 12-Jan-2018 | Current |
| Vikash Mishra | Director | 12-Jan-2018 | Current |
Financial Performance of Chimera Translational Research Fraternity.
Chimera Translational Research Fraternity Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 9.06% decrease. The company also saw a substantial improvement in profitability, with a 29.61% increase in profit. The company's net worth observed a substantial decline by a decrease of 55.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chimera Translational Research Fraternity?
Unlock access to Chimera Translational Research Fraternity's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Chimera Translational Research Fraternity?
Unlock and access historical data on people associated with Chimera Translational Research Fraternity, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chimera Translational Research Fraternity, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chimera Translational Research Fraternity's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
